Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
pubmed:
25
11
2020
medline:
24
12
2021
entrez:
24
11
2020
Statut:
ppublish
Résumé
Body dysmorphic disorder (BDD) is characterized by a preoccupation with a perceived appearance flaw or flaws that are not observable to others. BDD is associated with distress and impairment of functioning. Psychiatric comorbidities, including depression, social anxiety, and obsessive-compulsive disorder are common and impact treatment. Treatment should encompass psychoeducation, particularly addressing the dangers associated with cosmetic procedures, and may require high doses of selective serotonin reuptake inhibitors* (SSRI*) and protracted periods to establish full benefit. If there is an inadequate response to SSRIs, various adjunctive medications can be employed including atypical antipsychotics*, anxiolytics*, and the anticonvulsant levetiracetam*. However, large-scale randomized controlled trials are lacking and BDD is not an approved indication for these medications. Oxytocin* may have a potential role in treating BDD, but this requires further exploration. Cognitive-behavioural therapy has good evidence for efficacy for BDD, and on-line and telephone-assisted forms of therapy are showing promise. CBT for BDD should be customized to address such issues as mirror use, perturbations of gaze, and misinterpretation of others' emotions, as well as overvalued ideas about how others view the individual.
Identifiants
pubmed: 33230025
pii: 00004850-202103000-00001
doi: 10.1097/YIC.0000000000000342
pmc: PMC7846290
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-75Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Albertini RS, Phillips KA. (1999). Thirty-three cases of body dysmorphic disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry. 38:453–459.
Allen A, Hadley SJ, Kaplan A, Simeon D, Friedberg J, Priday L, et al. (2008). An open-label trial of venlafaxine in body dysmorphic disorder. CNS Spectr. 13:138–144.
Angelakis I, Gooding PA, Panagioti M. (2016). Suicidality in body dysmorphic disorder (BDD): a systematic review with meta-analysis. Clin Psychol Rev. 49:55–66.
American College of Obstetricians and Gynaecologists (2017). Committee Opinion No. 686. https://www.acog.org/search#q=labiaplasty&sort=relevancy .
American College of Obstetricians and Gynaecologists (2020). Committee Opinion No. 795. https://www.acog.org/search#q=labiaplasty&sort=relevancy .
American Psychiatric Association (1980). The Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV) Washington DC: American Psychiatric Association.
American Psychiatric Association (2007). Practice Guideline for the Treatment of Patients with Obsessive-Compulsive Disorder. Arlington, VA: American Psychiatric Association.
American Psychiatric Association (2013). The Diagnostic and Statistical Manual of Mental Disorders. 5th ed (DSM-5) Washington DC: American Psychiatric Association.
Beilharz F, Castle DJ, Grace S, Rossell SL. (2017). A systematic review of visual processing and associated treatments in body dysmorphic disorder. Acta Psychiatr Scand. 136:16–36.
Beilharz F, Castle DJ, Phillipou A, Rossell SL. (2018). Visual training program for body dysmorphic disorder: protocol for a novel intervention pilot and feasibility trial. Pilot Feasibility Stud. 4:189.
Beilharz F, Phillipou A, Castle DJ, Rossell S. (2020). Saccadic eye movements in body dysmorphic disorder. J Obsessive Compulsive Disorders. 25:100526, 1–6.
Blomeley D, Phillipou A, Castle DJ. (2018) Sizing it up: a systematic review of the nosology of muscle dysmorphia. Clinical Res Psychology. 1:1–10.
Bluett EJ, Homan KJ, Morrison KL, Levin ME, Twohig MP.. (2014). Acceptance and Commitment Therapy for anxiety and OCD spectrum disorders: an empirical review. J Anxiety Disord. 28:612–624.
Brakoulias V, Stockings E. (2019). A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder. Expert Opin Pharmacother. 20:47–53.
Brotman AW, Jenike MA. (1984). Monosymptomatic hypochondriasis treated with tricyclic antidepressants. Am J Psychiatry. 141:1608–1609.
Buhlmann U, Etcoff NL, Wilhelm S. (2006). Emotion recognition bias for contempt and anger in body dysmorphic disorder. J Psychiatr Res. 40:105–111.
Buhlmann U, Gleiss MJ, Rupf L, Zschenderlein K, Kathmann N. (2011). Modifying emotion recognition deficits in body dysmorphic disorder: an experimental investigation. Depress Anxiety. 28:924–931.
Buhlmann U, McNally RJ, Etcoff NL, Tuschen-Caffier B, Wilhelm S. (2004). Emotion recognition deficits in body dysmorphic disorder. J Psychiatr Res. 38:201–206.
Buhlmann U, McNally RJ, Wilhelm S, Florin I. (2002). Selective processing of emotional information in body dysmorphic disorder. J Anxiety Disord. 16:289–298.
Castle DJ, Rossell S, Kyrios M.. (2006). Body dysmorphic disorder. Psychiatr Clin North Am. 29:521–538.
Crerand CE, Phillips KA, Menard W, Fay C. (2005). Nonpsychiatric medical treatment of body dysmorphic disorder. Psychosomatics. 46:549–555.
Cuijpers P, Driessen E, Hollon SD, van Oppen P, Barth J, Andersson G. (2012). The efficacy of non-directive supportive therapy for adult depression: a meta-analysis. Clin Psychol Rev. 32:280–291.
Dong N, Nezgovorova V, Hong K, Hollander E. (2019). Pharmacotherapy in body dysmorphic disorder: relapse prevention and novel treatments. Expert Opin Pharmacother. 20:1211–1219.
Dufresne RG, Phillips KA, Vittorio CC, Wilkel CS. (2001). A screening questionnaire for body dysmorphic disorder in a cosmetic dermatologic surgery practice. Dermatol Surg. 27:457–462.
Enander J, Ivanov VZ, Andersson E, Mataix-Cols D, Ljótsson B, Rück C. (2014). Therapist-guided, Internet-based cognitive-behavioural therapy for body dysmorphic disorder (BDD-NET): a feasibility study. BMJ Open. 4:e005923.
Enander J, Andersson E, Mataix-Cols D, Lichtenstein L, Alström K, Andersson G, et al. (2016). Therapist guided internet based cognitive behavioural therapy for body dysmorphic disorder: single blind randomised controlled trial. BMJ. 352:i241.
Enander J, Ljótsson B, Anderhell L, Runeborg M, Flygare O, Cottman O, et al. (2019). Long-term outcome of therapist-guided internet-based cognitive behavioural therapy for body dysmorphic disorder (BDD-NET): a naturalistic 2-year follow-up after a randomised controlled trial. BMJ Open. 9:e024307.
Fang A, Lawson EA, Wilhelm S. (2019). Intranasal oxytocin modulates higher order social cognition in body dysmorphic disorder. Depress Anxiety. 36:153–161.
Fernandez de la Cruz L, Enander J, Ruck C, Wilhelm S, Phillips KA, Steketee G, et al. (2019). Empirically defining treatment response and remission in body dysmorphic disorder. Psychol Med. 1–7. doi: 10.1017/S0033291719003003. [Online ahead of print]
doi: 10.1017/S0033291719003003
Feusner JD, Bystritsky A, Hellemann G, Bookheimer S. (2010). Impaired identity recognition of faces with emotional expressions in body dysmorphic disorder. Psychiatry Res. 179:318–323.
Feusner JD, Townsend J, Bystritsky A, Bookheimer S. (2006). Visual information processing of faces in body dysmorphic disorder. Neuropsychopharmacology. 31:S210–S211.
Fineberg NA, Hollander E, Pallanti S, Walitza S, Grünblatt E, Dell’Osso BM, et al. (2020). Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. Int Clin Psychopharmacol. 35:173–193.
Gadel R, Coen C, Seassau M, et al. (2012). First results from an antisaccade task and memory-guided saccade task in a neurodevelopmental approach to schizophrenia. Schizophrenia Res. 136: S324–S324.
Gazzarrini D, Perugi G. (2017). Gender and body dysmorphic disorder. Body Dysmorphic Disorder: Advances in Research and Clinical Practice. Phillips KA., ed. In: New York, NY: Oxford University Press.
Gentile AJ, La Lima C, Flygare O, Enander J, Wilhelm S, Mataix-Cols D, Rück C. (2019). Internet-based, therapist-guided, cognitive-behavioural therapy for body dysmorphic disorder with global eligibility for inclusion: an uncontrolled pilot study. BMJ Open. 9:e024693.
Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, et al. (1990). Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 47:577–585.
Goulia P, Mantas C, Bassukas ID, Hyphantis T. (2011). Treatment with risperidone and venlafaxine of a patient with double-coded diagnosis of body dysmorphic disorder and delusional disorder somatic type. Hippokratia. 15:286–287.
Grace SA, Labuschagne I, Kaplan RA, Rossell SL. (2017). The neurobiology of body dysmorphic disorder: a systematic review and theoretical model. Neurosci Biobehav Rev. 83:83–96.
Grace SA, Toh WL, Buchanan B, Castle DJ, Rossell SL. (2019a). Impaired recognition of negative facial emotions in body dysmorphic disorder. J Int Neuropsychol Soc. 25:884–889.
Grace SA, Labuschagne I, Castle DJ, Rossell SL. (2019b). Intranasal oxytocin alters amygdala-temporal resting-state functional connectivity in body dysmorphic disorder: a double-blind placebo-controlled randomized trial. Psychoneuroendocrinology. 107:179–186.
Grant JE. (2001). Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report. J Clin Psychiatry. 62:297–298.
Grant JE, Phillips KA. (2004). Is anorexia nervosa a subtype of body dysmorphic disorder? Harv Rev Psychiatry. 12:123–126.
Greenberg JL, Mothi SS, Wilhelm S. (2016). Cognitive-behavioral therapy for adolescent body dysmorphic disorder: a pilot study. Behav Ther. 47:213–224.
Greenberg JL, Reuman L, Hartmann AS, Kasarskis I, Wilhelm S. (2014). Visual hot spots: an eye tracking study of attention bias in body dysmorphic disorder. J Psychiatr Res. 57:125–132.
Grocholewski A, Kliem S, Heinrichs N. (2012). Selective attention to imagined facial ugliness is specific to body dysmorphic disorder. Body Image. 9:261–269.
Gunstad J, Phillips KA. (2003). Axis I comorbidity in body dysmorphic disorder. Compr Psychiatry. 44:270–276.
Harrison A, Fernandes de la Cruz L, Enander J, Radua J, Mataix-Cols D. (2016). Cognitive behavioural therapy for body dysmorphic disorder: a systematic review and meta-analysis of randomised controlled trials. Clin Psychol Rev. 48:43–51.
Hollander E, Allen A, Kwon J, Aronowitz B, Schmeidler J, Wong C, Simeon D. (1999). Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 56:1033–1039.
Honigman RJ, Phillips KA, Castle DJ. (2004). A review of psychosocial outcomes for patients seeking cosmetic surgery. Plast Reconstr Surg. 113:1229–1237.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 394:939–951.
Hutton LMJ, Cave AJ, St-Jean R, Banh HL. (2017). Should we be worried about QTc prolongation using citalopram? A review. J Pharm Pract. 30:353–358.
Jenike MA. (1984). A case report of successful treatment of dysmorphophobia with tranylcypromine. Am J Psychiatry. 141:1463–1464.
Jefferies K, Laws K, Fineberg NA. (2012). Superior face recognition in body dysmorphic disorder. J Obsessive-Compulsive Related Disorders. 1: 175–179.
Jefferies-Sewell K, Chamberlain SR, Fineberg NA, Laws KR. (2017). Cognitive dysfunction in body dysmorphic disorder: new implications for nosological systems and neurobiological models. CNS Spectr. 22:51–60.
Karoumi B, Ventre-Dominey J, Vighetto A, Dalery J, d’Amato T. (1998). Saccadic eye movements in schizophrenic patients. Psychiatry Res. 77:9–19.
Kim D, Ryba NL, Kalabalik J, Westrich L. (2018). Critical review of the use of second-generation antipsychotics in obsessive–compulsive and related disorders. Drugs R D. 18:167–189.
Kimchi R. (1992). Primacy of holistic processing and global/local paradigm: a critical review. Psychological Bulletin. 112: 24–38.
Koran LM, Abujaoude E, Large MD, Serpe RT. (2008). The prevalence of body dysmorphic disorder in the United States adult population. CNS Spectr. 13:316–322.
Labuschagne I, Dunai J, Castle DJ, Kyrios M, Rossell SL. (2010). An examination of cognitive styles in body dysmorphic disorder (BDD), particularly their delusional thinking. Aust N Z J Psychiatry. 44: 706–712.
Landgraf S, Amado I, Bourdel MC, Leonardi S, Krebs MO. (2008). Memory-guided saccade abnormalities in schizophrenic patients and their healthy, full biological siblings. Psychol Med. 38:861–870.
Love BC, Rouder JN, Wisniewski EJ. (1999). A structural account of global and local processing. Cogn Psychol. 38:291–316.
Lusicic A, Schruers KR, Pallanti S, Castle DJ. (2018). Transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder: current perspectives. Neuropsychiatr Dis Treat. 14:1721–1736.
Mahato RS, San Gabriel MC, Longshore CT, Schnur DB. (2016). A case of treatment-resistant depression and body dysmorphic disorder: the role of electroconvulsive therapy revisited. Innov Clin Neurosci. 13:37–40.
Malcolm A, Labuschagne I, Castle D, Terrett G, Rendell PG, Rossell SL. (2018). The relationship between body dysmorphic disorder and obsessive-compulsive disorder: a systematic review of direct comparative studies. Aust N Z J Psychiatry. 52:1030–1049.
Mancuso SG, Knoesen NP, Castle DJ. (2010). Delusional versus nondelusional body dysmorphic disorder. Compr Psychiatry. 51:177–182.
Mataix-Cols D, de la Cruz LF, Isomura K, Anson M, Turner C, Monzani B, et al. (2015) A pilot randomised controlled trial of cognitive-behavioral therapy for adolescents with body dysmorphic disorder. J Am Acad Child Adolesc Psychiatry. 54:895–904.
McDowell JE, Farber RH, Clementz BA. (1995). Memory-guided saccade performance among schizophrenia and obsessive-compulsive disorder patients. Schizophrenia Res. 15:180–181.
McKay D, Todaro J, Neziroglu F, Campisi T, Moritz EK, Yaryura-Tobias JA. (1997). Body dysmorphic disorder: a preliminary evaluation of treatment and maintenance using exposure with response prevention. Behav Res Ther. 35:67–70.
Menin DS. (2019). Identifying efficacious treatment elements for refractory conditions, such as body dysmorphic disorder. JAMA Psychiatry. 76:357–358.
Menkes D, Bosanac P, Castle DJ. (2016). MAOIs: does the evidence warrant their resurrection? Australasian Psychiatry. 24:371–373.
Nakaaki S, Murata Y, Furukawa TA. (2008). Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder. Psychiatry Clin Neurosci. 62:370.
Oosthuizen P, Lambert T, Castle DJ. (1998). Dysmorphic concern: prevalence and associations with clinical variables. Aust N Z J Psychiatry. 32:129–132.
Pallanti S, Koran LM. (1996). Intravenous, pulse-loaded clomipramine in body dysmorphic disorder: two case reports. CNS Spectrums. 1:54–57.
Phillipou A, Rossell SL, Castle DJ, Gurvich C, Abel LA. (2014). Square wave jerks and anxiety as distinctive biomarkers for anorexia nervosa. Invest Ophthalmol Vis Sci. 55:8366.
Phillipou A, Rossell SL, Wilding HE, Castle DJ. (2016a). Randomised controlled trials of psychological & pharmacological treatments for body dysmorphic disorder: a systematic review. Psychiatry Res. 245:179–185.
Phillipou A, Rossell SL, Gurvich C, Castle DJ, Abel LA. (2016b). The eyes have it: eye movements and anorexia nervosa. Aust N Z J Psychiatry. 50:806–807.
Phillipou A, Castle DJ, Rossell SL. (2019). Direct comparisons of anorexia nervosa and body dysmorphic disorder: a systematic review. Psychiatry Res. 274:129–137.
Phillips KA. (2005a). Olanzapine augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry. 162:1022–1023.
Phillips KA. (2005b). Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry. 162:377–379.
Phillips KA. (1996a). The Broken Mirror: Understanding and Treating Body Dysmorphic Disorder. New York, NY: Oxford University Press.
Phillips KA. (1996b). An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder. Psychopharmacol Bull. 32:175–180.
Phillips KA, Hollander E, Rasmussen SA, Aronowitz BR, DeCaria C, Goodman WK. (1997). A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull. 33:17–22.
Phillips KA, Dwight MM, McElroy SL. (1998). Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 59:165–171.
Phillips KA. (2006). An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol. 21:177–179.
Phillips KA. (2017). Pharmacotherapy and other somatic treatments for body dysmorphic disorder. Body Dysmorphic Disorder: Advances in Research and Clinical Practice. Phillips KA., editor. In: New York, NY: Oxford University Press.
Phillips KA, Albertini RS, Siniscalchi JM, Khan A, Robinson M. (2001). Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J Clin Psychiatry. 62:721–727.
Phillips KA, Atala KD, Albertini RS. (1995). Case study: body dysmorphic disorder in adolescents. J Am Acad Child Adolesc Psychiatry. 34:1216–1220.
Phillips KA, Grant J, Siniscalchi J, Albertini RS. (2001). Surgical and nonpsychiatric medical treatment of patients with body dysmorphic disorder. Psychosomatics. 42:504–510.
Phillips KA, Kelly MM. (2009). Suicidality in a placebo-controlled fluoxetine study of body dysmorphic disorder. Int Clin Psychopharmacol. 24:26–28.
Phillips KA, Menard W. (2006). Suicidality in body dysmorphic disorder: a prospective study. Am J Psychiatry. 163:1280–1282.
Phillips KA, Menard W, Quinn E, Didie ER, Stout RL. (2013). A four-year prospective observational follow-up study of course and predictors of course in body dysmorphic disorder. Psychological Medicine. 43: 1109–1117.
Phillips KA, Najjar F. (2003). An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry. 64:715–720.
Phillips KA, McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI. (1993). Body dysmorphic disorder: 30 cases of imagined ugliness. Am J Psychiatry. 150:302–308.
Phillips KA, McElroy SL, Keck PE Jr, Hudson JI, Pope HG Jr. (1994). A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases. Psychopharmacol Bull. 30:179–186.
Phillips KA, Albertini RS, Rasmussen SA. (2002). A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 59:381–388.
Phillips KA, Menard W, Fay C, Weisberg R. (2005). Demographic characteristics, phenomenology, comorbidity, and family history in 200 individuals with body dysmorphic disorder. Psychosomatics. 46:317–325.
Phillips KA, Keshaviah A, Dougherty DD, Stout RL, Menard W, Wilhelm S. (2016). Pharmacotherapy relapse prevention in body dysmorphic disorder: a double-blind, placebo-controlled trial. Am J Psychiatry. 173:887–895.
Rabiei M, Mulkens S, Kalantari M, Molavi H, Bahrami F. (2012) Metacognitive therapy for body dysmorphic disorder patients in Iran: a proof of concept study. J Behav Ther Exp Psychiatry. 43:724–729.
Rashid H, Khan AA, Fineberg NA. (2014). Adjunctive antipsychotic in the treatment of body dysmorphic disorder – a retrospective naturalistic case note study. Int J Psychiatry Clin Pract.28:1–6.
Read J, Williams J. (2018). Adverse effects of antidepressants reported by a large international cohort: emotional blunting, suicidality and withdrawal effects. Current Drug Safety. 13:176–186.
Rief W, Buhlmann U, Wilhelm S, Borkenhagen A, Brahler E. (2006) The prevalence of body dysmorphic disorder: a population-based survey. Psychological Medicine. 36:877–885.
Rosen JC, Reiter J, Orosan P. (1995). Cognitive-behavioral body image therapy for body dysmorphic disorder. J Consult Clin Psychol. 63:263–269.
Rossell SL, Harrison BJ, Castle D. (2015). Can understanding the neurobiology of body dysmorphic disorder inform treatment? Australasian Psychiatry. 23: 361–364.
Rossell SL, Labuschagne I, Castle DJ, Toh WL. (2020). Delusional themes in Body Dysmorphic Disorder (BDD): comparisons with psychotic disorders and non-clinical controls. Psychiatry Research. 284:112694.
Schieber K, Kollei I, de Zwaan M, Martin A. (2015). Classification of body dysmorphic disorder: what is the advantage of the new DSM- 5 criteria? J Psychosomatic Research. 78:223–227.
Simberlund J, Hollander E. (2017). The relationship of body dysmorphic disorder to obsessive-compulsive disorder and the concept of the obsessive-compulsive spectrum. Phillips KA. (editor). In: Body Dysmorphic Disorder: Advances in Research and Clinical Practice. New York, NY: Oxford University Press.
Tignol J, Biraben-Gotzamanis L, Martin-Guehl C, Grabot D, Aouizerate B. (2007). Body dysmorphic disorder and cosmetic surgery: evolution of 24 subjects with a minimal defect in appearance 5 years after their request for cosmetic surgery. Eur Psychiatry. 22:520–524.
Tyagi H, Govender A, Drummond LM. (2012). Gender Differences in Body Dysmorphic Disorder. Philadelphia: 165th Annual Meeting of the American Psychiatric Association.
Tod D, Edwards C, Cranswick I. (2016). Muscle dysmorphia: current insights. Psychol Res Behav Manag. 9:179–188.
Toh WL, Castle DJ, Rossell SL. (2015). Facial affect recognition in body dysmorphic disorder versus obsessive-compulsive disorder: an eye-tracking study. J Anxiety Disord. 35:49–59.
Toh WL, Castle DJ, Rossell SL. (2017a). How individuals with body dysmorphic disorder (BDD) process their own face: a quantitative and qualitative investigation based on an eye-tracking paradigm. Cogn Neuropsychiatry. 22:213–232.
Toh WL, Castle DJ, Mountjoy RL, Buchanan B, Farhall J, Rossell SL. (2017b). Insight in body dysmorphic disorder (BDD) relative to obsessive-compulsive disorder (OCD) and psychotic disorders: revisiting this issue in light of DSM-5. Comprehensive Psychiatry. 77:100–108.
Toh WL, Castle DJ, Rossell SL. (2017c). Characterisation of body dysmorphic disorder (BDD) versus obsessive-compulsive disorder: in light of current DMS-5 nosology. J Obsessive-Compulsive Related Disorders. 12:117–126.
Uzun O, Ozdemir B. (2010). Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder. Clinical Drug Investigation. 30:707–710.
Veale D. (2000). Outcome of cosmetic surgery and DIY surgery in patients with body dysmorphic disorder. Psychiatric Bulletin. 24:218–221.
Veale D, Matsunaga H. (2014). Body dysmorphic disorder and olfactory reference disorder: proposals for ICD-11. Brazilian J Psychiatry. 36 (Suppl 1):14–20.
Veale D, Neziroglu F. (2010). Body Dysmorphic Disorder: A Treatment Manual. Chichester: Wiley.
Veale D, Willson R, Clark A. (2009). Overcoming body image problems (including body dysmorphic disorder). London: Constable Robinson.
Veale D, Anson M, Miles S, Pieta M, Costa A, Ellison N. (2014). Efficacy of cognitive behaviour therapy versus anxiety management for body dysmorphic disorder: a randomised controlled trial. Psychother Psychosom. 83:341–353.
Veale D, Gournay K, Dryden W, Boocock A, Shah F, Willson R, Walburn J. (1996). Body dysmorphic disorder: a cognitive behavioural model and pilot randomised controlled trial. Behav Res Ther. 34:717–729.
Veale D, Ellison N, Werner T, Dodhia R, Serfaty M, Clarke A. (2012). Development of a Cosmetic Procedure Screening Questionnaire (COPS) for body dysmorphic disorder. J Plast Reconstr Aesthet Surg. 65:530–532.
Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J. (2014). Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. 14:317.
Veale D, Gledhill LJ, Christodoulou P, Hodsoll J. (2016). Body dysmorphic disorder in different settings: a systematic review and estimated weighted prevalence. Body Image. 18:168–186.
Veale D, Phillips KA, Neziroglu F. (2017). Challenges in assessing and treating patients with body dysmorphic disorder and recommended approaches. Body Dysmorphic Disorder: Advances in Research and Clinical Practice. Phillips KA., editor. In: New York, NY: Oxford University Press.
Weingarden H, Mothi SS, Ladis I.. (2019). D-cycloserine-augmented behavior therapy for body dysmorphic disorder: a preliminary efficacy trial. Cognitive Therapy and Research. 43:937–947.
Wilhelm S. (2006). Feeling good about the way you look: A program for overcoming body image problems. New York, NY: Guilford Press.
Wilhelm S, Phillips KA, Steketee G. (2013). A cognitive behavioral treatment manual for body dysmorphic disorder. New York, NY: Guilford Press.
Wilhelm S, Phillips KA, Didie E, Buhlmann U, Greenberg JL, Fama JM, et al. (2014). Modular cognitive-behavioural therapy for body dysmorphic disorder: a randomised controlled trial. Behav Res Ther. 45:314–327.
Wilhelm S, Phillips KA, Greenberg JL, O’Keefe SM, Hoeppner SS, Keshaviah A, et al. (2019). Efficacy and posttreatment effects of therapist-delivered cognitive behavioral therapy vs supportive psychotherapy for adults with body dysmorphic disorder: a randomized clinical trial. JAMA Psychiatry. 76:363–373.
Wilhelm S, Weingarden H, Greenberg JL, McCoy TH, Ladis I, Summers BJ, et al. (2020). Development and pilot testing of a cognitive-behavioral therapy digital service for body dysmorphic disorder. Behav Ther. 51:15–26.
Williams J, Hadjistavropoulos T, Sharpe D. (2006). A meta-analysis of psychological and pharmacological treatments for Body Dysmorphic Disorder. Behav Res Ther. 44:99–111.